대한임상미생물학회


EUCAST news and updates (2024.06.04)

  • 작성자

    홍성근
  • 작성일자

    2024-06-04 16:06
  • 조회수

    55

 

EUCAST Logo  

EUCAST news and updates

Dear colleagues,

The following news items have been published in the previous month:

  • 28 May 2024:  Updated version of "Guidance on intrevenous use of fosfomycin"

    The guidance document on "Intravenous use of fosfomycin" updated. See guidance documents.

     

  • 22 May 2024:  Aztreonam-avibactam and cefepime-enmetazobactam breakpoints published

    MIC and zone diameter breakpoints for aztreonam-avibactam and cefepime-enmetazobactam are now available as addenda to the clinical breakpoint table 14.0. 

     

    The breakpoints will be integrated in the regular breakpoint table 15.0, 1 Jan, 2025. 

     

     

     

  • 19 May 2024:  The Belgian NAC presented

    A presentation of the Belgian NAC is posted. 

     

  • 11 May 2024:  General Committee 2024 meeting - minutes published

    The EUCAST General Committee meeting 2024 was held in Barcelona during ESCMID Global. The minutes are now available.

     

  • 07 May 2024:  Proposed change of breakpoints for aminopenicillins in enterococci

     

    Proposed change of breakpoints for aminopenicillins in enterococci (consultation period 7 May - 14 June, 2024). 

    Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Comments not entered into the designated document will not be considered (download form for comments). 

     

     

  • 03 May 2024:  Consultation: benzylpenicillin breakpoints for S.pneumoniae and Viridans group streptococci

    EUCAST consultation (3 May - 14 June) on breakpoints for Streptococcus pneumoniae and viridans group streptococci.

     

  • 03 May 2024:  Aztreonam-avibactam and cefepime-enmetazobactam now available.

    Aztreonam-avibactam has now obtained regulatory approval and breakpoints from EMA and EUCAST for Enterobacterales.

     

    These are S≤4, R>4 mg/L. Disk diffusion criteria and QC targets and ranges will be published shortly. There are no breakpoints for other species.

     

    Cefepime-enmtazobactam has now obtained regulatory approval breakpoints from EMA and EUCAST for Enterobacterales.

     

    These  are S≤4, R>4 mg/L. Disk diffusion criteria and QC targets and ranges will be published shortly. There are no breakpoints for other species.

     

    The new agents will be part of the next EUCAST breakpoint table 15.0 (1st of January 2025). In the meantime we will soon publish an addendum for the two agents with information on disk contents (potencies), zone diameter correlates and QC criteria.

     


Please visit the EUCAST News page to read more.

All changes to the EUCAST website and to AST recommendations and guidance are listed in a table on the EUCAST website!

With kind regards,
EUCAST

 
 
  ESCMID Executive Office
Aeschenvorstadt 55
4051 Basel
Switzerland
Phone +41 61 508 0150
info@escmid.org
www.escmid.org
Follow ESCMID
Follow us on mastodon Visit us on LinkedIn Visit us on YouTube
The EUCAST Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of EUCAST-related matters and other information of interest to professionals in the infection field.